Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1061-1080 of 1,694 trials

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Parkinson's Disease: BIIB122 Treatment Study

We are studying the safety and effects of BIIB122 in people with LRRK2-associated Parkinson's disease. This trial aims to understand how well the treatment engages important biological pathways.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Type 2 Diabetes: Comparing Empagliflozin, Pioglitazone, and Semaglutide

We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.

Type 2 Diabetes6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Cardiovascular Disease Prevention: Personalized Statin Therapy

We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.

High Genetic Risk for Coronary Artery Disease1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: Trametinib and Hydrochloroquine Study

We are exploring a new treatment combination for patients with metastatic pancreatic cancer to see if it helps improve survival and understand resistance to therapy. This study aims to assess safety and effectiveness while analyzing how the cancer may resist treatment.

Metastatic Pancreatic CancerEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Cortisone Treatment for Children with Facial Nerve Palsy

We are studying whether cortisone can help children with acute facial nerve paralysis recover better than a placebo. The trial will also look at safety and how the condition affects daily life.

Facial Nerve Palsy (Bell's Palsy)>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyPediatrics

Cancer Treatments: Impact on Speech and Quality of Life

We are studying how different cancer treatments affect speech understanding in noise and overall quality of life for patients. This research may help us understand the cognitive effects of these treatments over time.

Bladder CancerTesticular SeminomaHead and Neck Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesOncologyPsychiatry

Colon Cancer: Dostarlimab with CAPEOX

We are studying a new treatment combining dostarlimab with CAPEOX for people with untreated Stage III colon cancer. The goal is to see if this combination is more effective and safe compared to CAPEOX alone.

Metastatic Colon CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Recurrent Meningioma: [177Lu]Lu-DOTATATE Treatment Study

We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.

Meningioma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Acute Bacterial Prostatitis: Fosfomycin vs. Cefixime

We are comparing two oral antibiotics to see which one better resolves urinary symptoms in men with acute bacterial prostatitis. The study will also look at any side effects and the effectiveness of the treatments over time.

Acute Bacterial Prostatitis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesUrology

Multiple Sclerosis: Treatment Withdrawal Study for Older Adults

We are investigating whether stopping disease-modifying therapies is safe for people aged 55 and over with inactive relapsing-remitting multiple sclerosis. The study will help us understand its effects on relapse rates, disability, and quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Glioblastoma Treatment: Optune with Pembrolizumab

We are testing whether adding pembrolizumab to Optune and temozolomide improves survival for newly diagnosed glioblastoma patients compared to a placebo. This study aims to understand the effectiveness and safety of this treatment combination.

Newly Diagnosed Glioblastoma>2 yearsConfirmation phase (III)Standard MedicinesOncology

Generalized Anxiety Disorder: MM120 Medication Study

We are testing a new oral medication, MM120, to see if it helps reduce anxiety symptoms in adults with generalized anxiety disorder. The study will also look at its effects on quality of life and sexual functioning.

Generalized Anxiety Disorder1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePsychiatry

BRAF Alterations in Cancer: FORE8394 Treatment Study

We are testing the drug FORE8394 in patients with advanced solid tumors or specific brain tumors that have BRAF alterations. The goal is to see if it can effectively treat these cancers.

BRAF Gene MutationEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

OM85 for Preventing Respiratory Infections in Elderly Patients

We are studying whether the drug OM85 can help reduce respiratory infections in elderly individuals living in healthcare residences. This trial will also look at hospital visits and antibiotic use related to these infections.

Recurrent Respiratory Tract InfectionsMonitoring phase (IV)Standard MedicinesInternal MedicinePulmonology

COPD: Dronabinol for Breathlessness Relief

We are studying whether Dronabinol can help people with severe and very severe COPD experience less breathlessness. This trial will compare its effects against a placebo.

Chronic Obstructive Pulmonary Disease≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesInternal MedicinePulmonology

Migraine Prevention: Comparing Common Medications

We are studying how well different medications prevent migraines in primary care patients. This trial aims to find out which treatment reduces migraine days and improves quality of life.

Migraine Headaches≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Myomectomy: Misoprostol for Reducing Blood Loss

We are studying whether misoprostol can help reduce blood loss during myomectomy surgeries. This trial involves comparing its effects against a placebo in patients undergoing different surgical techniques.

Uterine FibroidsEfficacy phase (II)Standard MedicinesGynecology and Obstetrics